• 비만대사연구학술지
• /
• 제1권2호
• /
• pp.78-82
• /
• 2022

Liraglutide (Saxenda^R) is prescribed to induce and sustain weight loss in obese patients. The starting dose of liraglutide is 0.6 mg/day for 1 week, which is increased by 0.6 mg/day every week until the full maintenance dose of 3 mg/day is achieved. Such dose titration is needed to prevent side effects, which primarily include gastrointestinal problems such as nausea, diarrhea, constipation, vomiting, dyspepsia, and abdominal pain. A 35-year-old, reportedly healthy obese man receiving liraglutide treatment for obesity visited the emergency room complaining of generalized weakness and dizziness accompanied by repeated diarrhea and vomiting. He reported over 20 episodes of diarrhea starting the day after liraglutide dose escalation from 1.2 mg/day to 1.8 mg/day. Laboratory findings suggested pre-renal acute kidney injury, including serum creatinine 4.77 mg/dl, blood urea nitrogen (BUN) 37 mg/dl, estimated glomerular filtration rate (eGFR) 15 ml/min/1.73 m², and Fractional excretion of sodium 0.08. After volume repletion therapy, his renal function recovered to a normal range with laboratory values of creatinine 1.08 mg/dl, BUN 14 mg/dl, and eGFR 88 ml/min/1.73 m². This case emphasizes the need for caution when prescribing glucagon-like peptide-1 receptor agonists, including liraglutide, given the risk of serious renal impairments induced by volume depletion and dehydration through severe-grade diarrhea and vomiting.

• 동의생리병리학회지
• /
• 제36권5호
• /
• pp.155-162
• /
• 2022

Even after testing negative for COVID-19, some patients continue to struggle with a variety of symptoms such as fatigue, shortness of breath, gastrointestinal problems and neurological problems. The World Health Organization (WHO) defined long COVID (Post COVID-19 conditions) as "A disease occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months, that cannot be explained by an alternative diagnosis." As a possible pathological mechanism of long COVID, three hypotheses are proposed: the persistence of the infectious state due to the residual virus, the persistent inflammatory response, and the autoimmune response. The main symptoms of long COVID are shortness of breath (dyspnea), abdominal pain and dyspepsia, fatigue, cognitive problems (brain fog), anosmia and dysgeusia, and chest pain, palpitations and tachycardia. In the Chinese guidelines, COVID-19 patients were divided into mild, moderate, severe, and recovery, and prescriptions with effective therapeutic effects were summarized to encourage combined treatment of chinese and western medicine. Globally, only symptomatic therapy is recommended for long COVID, but a specific treatment has not yet been proposed. Recently, morbidity code for post COVID-19 conditions was created, and it is planned to announce guidelines for long COVID treatment and management in the first half of 2023. In line with this trend, the Korean medical community needs to make efforts to prepare treatment guidelines for patients with long COVID.

• Journal of Nutrition and Health
• /
• 제41권4호
• /
• pp.307-316
• /
• 2008

The purpose of the study was to investigate nutritional status of chronic obstructive pulmonary disease (COPD) patients and to find out the differences according to the stages of disease. From March to October, 2006, 41 stable male patients of mild to severe COPD patients were recruited from Seoul National University hospital. The patients' of body weight and fat free mass were assessed by bioelectrical impedance analysis. The nutritional status of the patients was also assessed by 3-day recall, index of nutritional quality (INQ), dietary diversity score (DDS), dietary variety score (DVS), food group index pattern and dietary quality index (DQI). The total of 41 patients were classified into three groups, stage I, stage II and stage III groups according to the classification of Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard. The mean age of the patients in each stage were 67.2-66.9 years showing no significant difference. The ratio of $FEV_1$/FVC were $57.5{\pm}7.3$, $46.9{\pm}7.6$ and $38.2{\pm}6.8%$, respectively showing significant differences according to the stages of disease. The fat free mass of the stage II ($48.2{\pm}4.7kg$) and III ($47.3{\pm}4.5kg$) was significantly lower than that of stage I ($53.1{\pm}6.9kg$) patients. There were significant correlation of fat free mass with $FEV_{1}$, and BMI (body mass index) with $FEV_{1}$/FVC ratio (p < 0.05). COPD patients showed the diet-related clinical symptoms of anorexia, dyspnea, dyspepsia, and chewing difficulty. Daily intakes of calorie, K, vitamin $B_2$ and folate of the patients were very low ($83.8{\pm}20.7%$, $58.9{\pm}14.4%$, $70.7{\pm}19.6%$ and $74.4{\pm}10.2%$, respectively) however, they did not significantly different according to the stages of disease. Daily intake of calcium was significantly lower in the stage III patients (p < 0.05). The mean scores of dietary variety score was significantly lower in the stage III patients (p < 0.001). Dietary quality index of the patients were not different among the stages of disease and the scores indicated poor quality of diet. As a summary, we found that body fat free mass, regularity of exercise, frequency of having snacks and dietary variety score were significantly associated with the severity of chronic obstructive pulmonary disease.

• Radiation Oncology Journal
• /
• 제19권1호
• /
• pp.34-39
• /
• 2001

목적 : 간암을 대상으로 한 고식적인 방사선치료가 아닌 정위방사선치료에 대한 보고는 매우 드물다. 이에 저자들은 원발성 간암환자들을 대상으로 정위방사선치료에 대한 예비결과를 알아보고자 하였다. 대상 및 방법 : 1999년 7월부터 2000년 3월까지 성모병원 치료방사선과에서 두개외 종양으로 정위방사선치료를 33명의 환자들에서 시행하였으며 그중 13명의 원발성 간암환자들을 대상으로 하였다. 대상환자들의 성별은 남자가 12명, 여자가 1명이었으며 연령분포은 $44\~66$세(중앙값:59세)였고 종양의 크기는 $10\~825\;cc$ (평균 : 185 cc)였다. 정위방사선치료는 1회 $3\~5\;Gy$를 $90\%$의 등선량 곡선에 기준하여 주 3-5회씩, $2\~3$주 동안 조사선량의 범위는 $30\~50\;Gy$이고 중앙선량은 50 Gy였다. 결과 : 추적관찰기간은 $3\~13$개월이었다(중간추적관찰기간: 8개월). 정위방사선치료 후 전체 환자에서 완전관해 $7.7\%$, 부분관해 $v$, 미세관해 $30.8\%$, 무반응 $7.7\%$였으며 국소제어율(완전관해+부분관해)은 $61.5\%$였다. 혈청 AFP의 치료 전과 치료 후 수치의 변화를 비교한 결과, 전체환자 중 $92.3\%$에서 AFP이 감소하였다. 치료에 따른 부작용은 소화장애가 $84.6\%$, 경한 오심이 $69.2\%$, 일시적인 간 기능의 저하가 $15.4\%$, 미열이 $7.7\%$에서 나타났으나 치명적인 부작용은 없었다. 결론 : 원발성 간암에 대한 정위방사선치료를 시행한 결과 비교적 안전하고 효과적인 치료방법이었다. 그러나 새로운 치료방법으로서 검증하기 위해서는 보다 많은 환자와 장기적인 추적관찰이 필요하리라고 사료된다.